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There is increasing pressure to provide cost-effective healthcare based on ‘‘best practice.’’
Consequently, new biomarkers are only likely to be introduced into routine clinical
biochemistry departments if they are supported by a strong evidence base and if the results
will improve patient management and outcome. This requires convincing evidence of the
beneﬁts of introducing the new test, ideally reﬂected in fewer hospital admissions, fewer
additional investigations and/or fewer clinic visits. Carefully designed audit and cost-beneﬁt
studies in relevant patient groups must demonstrate that introducing the biomarker delivers
an improved and more effective clinical pathway. From the laboratory perspective, pre-
analytical requirements must be thoroughly investigated at an early stage. Good stability of
the biomarker in relevant physiological matrices is essential to avoid the need for special
processing. Absence of speciﬁc timing requirements for sampling and knowledge of the
effect of medications that might be used to treat the patients in whom the biomarker will be
measured is also highly desirable. Analytically, automation is essential in modern high-
throughput clinical laboratories. Assays must therefore be robust, fulﬁlling standard
requirements for linearity on dilution, precision and reproducibility, both within- and
between-run. Provision of measurements by a limited number of specialized reference
laboratories may be most appropriate, especially when a new biomarker is ﬁrst introduced
into routine practice.
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1 Introduction
Despite numerous publications on biomarkers – a PubMed
search identiﬁes close to half a million articles since 1975 –
very few new tests have been added to the routine repertoire
of most clinical biochemistry laboratories during that time
period. Those that have been introduced on a large-scale
include immunoassays for CA125, prostate-speciﬁc antigen
(PSA) and cardiac troponin. Over the last 15 years, the
average rate of introduction of new protein analytes into
mainstream clinical laboratories is estimated to have been
only 1.5 new proteins per year [1]. In view of the major
expenditure on identifying and characterizing new biomar-
kers, particularly in the proteomics ﬁeld, it is desirable to
consider why this has been the case – since new technology
and diagnostic tests are clearly only of value if used and
adopted – and whether there are obstacles that can readily be
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introduction of new tests into clinical practice.
Taking a biomarker from the research laboratory
successfully into the routine clinical laboratory ideally
requires a four-way collaboration, involving the research
laboratory (which develops the fundamental concept), the
diagnostics industry (which turns the concept into a prac-
tical reliable tool), the clinical laboratory (which evaluates
the tool in real-life practice) and clinicians (who will help to
identify unanswered clinical questions and needs which
measurement of a new biomarker might usefully address as
well as provide the carefully characterized clinical speci-
mens necessary for its assessment).
Although the decision to introduce a new biomarker will
clearly be inﬂuenced by different reimbursement policies
(or lack of these) and other logistical arrangements in
different healthcare systems, the proposed introduction of a
new biomarker into routine clinical practice essentially
requires rigorous assessment from three different perspec-
tives – those of the clinician, the laboratorian and the
healthcare funding organization. In terms of the last, an
integrated approach to funding the entire patient-care
pathway, including additional tests recommended as parts
of other initiatives (e.g. Quality Outcome Framework targets
in the United Kingdom) rather than piecemeal funding of
separate functions (laboratory, pharmacy, radiology, etc.) –
sometimes termed ‘‘silo budgeting’’– would clearly be
highly desirable but is frequently not in place. In the United
States, gaining approval and payment rates for new tests can
be a limiting factor in determining whether a new test will
be performed [2].
From all three perspectives, it is essential that imple-
mentation of a new test should be evidence-based, although
other priorities may differ slightly. From the perspective of
the healthcare provider, for example, the new test must be
cost effective (e.g. facilitate admission reduction, decrease
length of stay in hospital or replace more expensive testing).
From a clinical perspective, a new test must provide infor-
mation that adds to or replaces information available from
existing tests and demonstrably improves patient outcome
(e.g. selects a cohort of patients likely to beneﬁt from costly
drugs). From a laboratory perspective, it must be possible to
incorporate the new test readily into the routine workﬂow
(e.g. it must have reasonably robust pre-analytical specimen
handling requirements), to control the workload post-intro-
duction and of course to fund the test. Funding is perhaps
most problematic as laboratories are currently under huge
pressure to reduce costs. Regrettably, it is rarely possible to
relate expenditure in one area (e.g. on calprotectin tests in
the laboratory) to resultant savings in another (e.g. conse-
quent requirement for fewer much more expensive colo-
noscopies), although this can be readily demonstrated by
economic modeling (British In Vitro Diagnostics Associa-
tion (BIVDA). BIVDA Manifesto: Unlocking the potential of
in vitro diagnostics in the National Health Service (NHS).
2010; http://www.bivda.co.uk). In this respect, it is salutary
to note that there is evidence of a severe problem of under-
utilization of some tests that would potentially beneﬁt
diagnosis. This is most likely to occur when laboratories or
health systems are operating on a ﬁxed budget and there is
major focus on over-utilization of tests, but it should be
addressed. Finally, for large-scale implementation of a new
test, input and investment from the diagnostics industry is
essential. The views of patient representatives may also be
helpful in relation both to test acceptability and possible
psychological implications.
This article focuses on the practical requirements for
successful introduction of a new biomarker from a labora-
tory perspective (Table 1), highlighting some differences in
approach in two fundamentally different healthcare
systems, those of the United Kingdom [3] and the United
States. (Although the United Kingdom now has four distinct
systems for health following devolution in 1999, all four
reﬂect the same basic principles.)
Some of the requirements for introducing a new
biomarker were considered speciﬁcally in March 2010 at the
‘‘Perspectives in Proteomics’’ Conference of which this
article forms part of this ‘‘Focus Issue’’, and also at the 12th
Bergmeyer Conference [4], which took place the same
month under the auspices of the International Federation of
Clinical Chemistry and Laboratory Medicine.
2 Transition of a new biomarker from
research to routine
It is immediately apparent after even superﬁcial review of
the relevant literature that many more biomarkers are
identiﬁed than ever reach routine practice. For the relatively
few that do so, the time frame is often years. The tumour
Table 1. Key points
(i) Taking a new biomarker from the research laboratory
into the routine clinical laboratory requires
proactive three-way collaboration involving the
research laboratory, the diagnostics industry and
the clinical laboratory.
(ii) Some tests may be most appropriately offered in
specialist laboratories.
(iii) Rigorous investigation of pre-analytical requirements
of a new biomarker is essential at the earliest
possible stage of evaluation.
(iv) Analytical performance must be documented in detail.
(v) Well-documented evidence of clinical utility and cost-
effectiveness in populations representative of those
which will be encountered in routine practice is
essential for a new biomarker.
(vi) Evidence is required of the additional diagnostic or
predictive information provided by the biomarker
when used together with or when replacing other
clinical or biochemical tests, i.e. its likely beneﬁcial
effect on the patient pathway.
(vii) Appropriate regulatory requirements must be fulﬁlled.
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identiﬁed in 1970 [5], but it was not until the late 1980s that
the ﬁrst deﬁnitive study investigating its clinical utility in
prostate cancer was published [6] and another decade later
until establishment of the 1st International Standard for
PSA [7]. As described later in this article, the example of
PSA illustrates very well some of the challenges likely
to be encountered during the introduction of a new diag-
nostic test into routine practice. The appropriate clinical
application and interpretation of PSA measurements
remain controversial even after many years of clinical use of
this test.
It is relevant to note that at the time PSA was initially
investigated, most routine clinical biochemistry laboratories
in the United Kingdom NHS had signiﬁcant research
capability, particularly in developing and optimizing
immunoassays. Much of this expertise has since been lost,
as recently highlighted in the report of an independent
review of NHS Pathology Services, which states that ‘‘In the
past one of the strengths of the NHS has been the inter-
relationship between service provision and research’’ (Lord
Carter of Coles. Report of the second phase of the review
of NHS pathology services in England 2008; http://
www.dh.gov.uk/en/Publicationsandstatistics/Publications/
PublicationsPolicyAndGuidance/DH_091985). Relevant to
this, a recent Science Council Report observed that ‘‘Of
special concern to us was the relatively low proﬁle of diag-
nostic testing and those who undertook this is in the
NHS’’ (The Science Council. Integration and implementa-
tion of diagnostic technologies in healthcare. 2004; http://
www.sciencecouncil.org).
This reduction in research capacity and lack of visibility,
both of which need to be urgently addressed, are among
several current barriers to innovation in the clinical labora-
tory. Increasing focus on service delivery has inevitably
meant less time for research activities, even those as rela-
tively straightforward as systematic storage of relevant
human biological specimens (http://www.dh.gov.uk/en/
Publicationsandstatistics/Publications/PublicationsPolicy
AndGuidance/DH_091985). Continual pressure to make
cost savings despite a relentlessly increasing workload
(frequently 8–10% per year, usually without matching
budget increases) [8] contributes to the perception that there
is no money available for research and the commonly held
but erroneous view that research is not an integral part of
the remit of a routine clinical laboratory. This view is
particularly unfortunate since laboratory staff – who have
relevant analytical expertise as well as unparalleled access to
clinical specimens – are uniquely well placed to contribute
constructively to the evaluation and evidence-based imple-
mentation of new tests. Current research needs and exper-
tise in clinical biochemistry may have diminished in the
realm of assay development, but there remains critical
expertise in the realms of analytical assessment, assay
standardization, quality assurance, assessment of reference
intervals, physiological variability, optimal specimen collec-
tion and processing, correlation with existing tests and
interpretation of results, all of which are essential to optimal
introduction of a new test. Such needs and expertise apply to
test development in the United States as well as in the
United Kingdom [2].
Such activity is in accord with increasing appreciation
that multidisciplinary input is highly desirable at all stages
of clinical evaluation of a new biomarker. Relevant to this, a
recent UK government strategy article highlights the
importance of research as a core NHS role, particularly
when resources are under pressure and there is increasing
need to identify new ways of preventing, diagnosing and
treating disease [9]. How best to direct the funding essential
for such activity into laboratory budgets requires careful and
innovative thought and should perhaps be considered by the
NHS Technology Adoption Centre (NTAC), whose remit
includes identifying those technologies which will provide
cost effective improved patient outcomes in the NHS
(http://www.technologyadoptionhub.nhs.uk/), but which
might itself require increased resources to achieve this.
Recommendations by the Medical Technologies Advisory
Committee (MTAC) of the National Institute of Health and
Clinical Excellence (NICE) should inform NTAC decisions
as MTAC is responsible for advising on which medical
technologies, including diagnostic tests, should be selected
for evaluation as well as developing the guidance itself
(NICE. New medical technologies programme. 2010; http://
www.nice.org.uk/).
The reduction universally observed in test development
and research activities represents in part a shift from
laboratories making their own reagents and immunoassays
to buying most of them from an in vitro diagnostics
company. This is not an entirely negative development.
External quality assessment (EQA)/proﬁciency testing data
clearly demonstrate the beneﬁts of automation, including
much improved precision, and there are beneﬁts of scale in
centralizing test development processes. Nevertheless, clin-
ical laboratories should play an active role in the ﬁnal
evaluation of assays and in study of their clinical utility.
In considering requirements for successful introduction
of new diagnostic tests, it is helpful to review the general
criteria that must be met (Table 2), focusing on the roles of
both research and specialist laboratories and the somewhat
different requirements of high-throughput routine labora-
tories.
2.1 Role of the research laboratory
Having selected a promising biomarker for further investi-
gation, it is essential from the earliest stages of evaluation to
minimize the risk of introducing methodological bias which
may lead to misinterpretation of results [10, 11]. This
requires considerable care and attention to detail with
respect to all phases of analysis when designing studies to
be undertaken [12].
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& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.comTable 2. Requirements for successful transition of a new biomarker from the research environment to routine clinical practice
Requirement Comment
An unmet clinical need which is clearly understood [33] The purpose of the test should be clear, its use evaluated within a
care pathway and its effect on outcome compared directly with
existing best practice in the population for which it is intended
[35].
Appropriate and well-characterized clinical specimens for both
discovery and qualiﬁcation which mirror the relevant clinical
population.
Numerous critical factors must be taken into account when
collecting specimens for the studies of new biomarkers, whether
for a speciﬁc clinical study or for a biobank, as has recently been
comprehensively reviewed [14]. It is highly desirable that the
results of parameters such as albumin, creatinine and CRP
should be available for banked specimens to enable
interpretation of results and ensure appropriate matching of
patient and control samples.
An appropriate and well-validated discovery platform which is
robust, reliable and relatively simple to operate.
The importance of using internal standards, identifying measured
components, developing standards for calibration and quality
control, identifying peaks in spectra and applying established
standards for method evaluation have previously been
highlighted [36].
Clinical evidence for the biomarker of Evidence of biomarker-disease association is necessary but not
sufﬁcient for effective clinical performance. The critical question
is ‘‘Do patients undergoing the diagnostic test fare better than
similar untested patients?’’ [37].
 Association with the relevant disease
 Assessment of clinical utility and impact
 Circumstances where use of the test would be unjustiﬁed
Rigorous early investigation of pre-analytical factors that might
inﬂuence interpretation of test results, including the effect of
Quality requirements previously described in detail for tumour
marker measurement using immunoassay, mass spectrometry
and microarray techniques are relevant to all new tests [23].  Specimen type, specimen timing and specimen handling
 Stability in transit and during long-term storage
 Freeze–thawing
 Intra-individual biological variation
 Relevant interventions (e.g. biopsy) or medication .
Analytical evidence for the biomarker measurement of acceptable
technical performance, including




A prototype assay method suitable for early evaluation Early transfer of a validated biomarker from the research laboratory
to a specialist referral laboratory enables conﬁrmation of
transferability and assessment in a clinical setting. Some tests
may be most appropriately provided by specialist laboratories
(as is current practice, e.g. for gut hormone screens) with
possible later transfer to a high-throughput laboratory.
Transfer of the biomarker to a routine IVD platform, which is only
likely if there is
This step represents much greater ﬁnancial investment than
development of the prototype method [33]. Introduction of a new
test onto an analytical platform may also require modiﬁcation of
existing tests with other implications (e.g. for product inserts,
etc.).
 Convincing evidence of sufﬁcient clinical utility to warrant broad
commercial uptake
 High likelihood that regulatory approval will be granted
Introduction of the biomarker into the routine clinical laboratory
requires
Commissioning diagnostic tests is more sophisticated than simply
procurement or contracting procedures. The core of the
commissioning process is identiﬁcation of the clinical need that
will be met by the use of the test and the contribution it will make
to the patient pathway [20].
 Commissioning the new test because it demonstrably meets an
identiﬁed clinical need
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laboratory
Sample collection, processing and storage protocols must be
conﬁrmed to be appropriate for each biomarker. Documents
describing international efforts to develop best practice have
recently been helpfully collated [13]. Relevant issues have also
been reviewed in more detail, both broadly, in relation to
banking of clinical samples for proteomic biomarker studies
[14], and more speciﬁcally, in relation to criteria for the UK
Biobank project [15]. The latter is a large prospective study in
which samples are being collected from 500000 participants
with the aim of investigating the role of a number of factors
in the causes of major diseases of late and middle age. The
type of sample, the collection tube and the presence of
stabilizers all need to be carefully considered. The storage
stability of a potential new biomarker should also be inves-
tigated at room temperature, 4 and 301C, together with the
effect of repeated freeze–thaw cycles. Specimen timing may
be critical if diurnal variation inﬂuences biomarker produc-
tion in vivo, as is the case even for some commonly measured
analytes such as cortisol. Early evaluation of intra-individual
variation [16] is important. Unless pathological variation of
biomarker values is substantially greater than physiological
variation from day to day, it is unlikely that the biomarker will
be clinically useful. This circumstance also contravenes the
major inconvenience and cost of arranging multiple
sampling on different days.
Ensuring that specimens are collected strictly according to
well-deﬁned protocols at the evaluation stage is essential to
minimize the risk of inadvertently introducing subtle differ-
ences in sample handling that may affect study results.
Selection of clinical specimens for study is, of course, also
critical. Appropriate age-matched controls are necessary to
minimize the risk of introducing extraneous confounding
factors and consequently possible misinterpretation. For
example, if evaluating a serum proteomics test for the diag-
nosis of prostate cancer in a male cohort with prostate cancer
and of average age 67 years, it is not appropriate for the
comparison group to have an average age 30 years less and
include 50% females [10]. It is also desirable that the patient
cohorts studied resemble as closely as possible the cohort
likely to be encountered in routine clinical practice and that
the control population is suitably diverse. Confounding
pathophysiological factors such as renal dysfunction, hepatic
disease, protein-losing disorders, acute-phase responses and
nutritional deﬁcits often may inﬂuence biomarker levels. For
banked specimens, availability of results for basic parameters
including serum albumin, creatinine and C-reactive protein
(CRP) is therefore highly desirable as these results may be
critical to the interpretation of results for a new biomarker.
The availability of such information also facilitates appropriate
matching of control and patient cohorts during biomarker
evaluation. If possible, disease and control specimens should
be collected at the same clinics to minimize possible local or
procedural differences.
2.1.2 Analytical considerations in the research
laboratory
Research laboratories differ from routine clinical laboratories
in several important respects. More staff time is likely to be
available for relatively complex experimental procedures that
are much less feasible in a busy routine laboratory. Early
consideration should therefore be given as to whether manual
assay procedures could be simpliﬁed and ultimately auto-
mated if the test is widely adopted. Quality control procedures
in a research laboratory may be less rigorous than those in a
clinical laboratory but basic steps should be implemented at
an early stage to assess reproducibility (both within- and
between-batch) and precision at clinically relevant concentra-
tions over a reasonable time period and across different
batches of reagents. The lowest reportable concentration,
using precision proﬁles [17], linearity on dilution and recovery
of added analyte should also be documented.
2.1.3 Post-analytical considerations in the research
laboratory
During early evaluation studies, it is highly desirable that
specimens examined are from cohorts of patients similar to
those likely to be encountered when using the test in a typical
clinical setting. The potential role of the biomarker in clinical
practice therefore needs to be considered in the design of early
studies of clinical validity, while accepting that this role is likely
to be reﬁned as its use increases [18]. For example, it was only
appreciated some time after free PSA measurement became
available that measurement of the free: total PSA ratio is
appropriate only when the total serum PSA concentration is
within certain limits. Excellent and early collaboration between
hospital and research laboratories – whether in academic
institutions or in diagnostic companies – should help to ensure
that specimens are relevant as well as encourage development
of processes that are robust enough for ultimate transfer to
routine laboratories. In this respect, the trend in the United
Kingdom towards the loss of joint academic and NHS clinical
biochemistry departments is unfortunate.
2.2 The role of the specialist laboratory
The specialist or referral laboratory can provide a very
helpful interim setting during the transition of a new
biomarker from research to routine clinical practice.
Specialist laboratories such as those forming the United
Kingdom Supra-regional Assay Service network (http://
www.sas-centre.org/home.html) generally provide assays
which meet at least one of the following criteria:
(i) Small workload (e.g. gut hormones)
(ii) Relevant only in rare clinical condition/s (e.g. parathyroid
hormone-related peptide)
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(e.g. extraction assays for steroids)
(iv) Clinical interpretation complex and requiring specialist
expertise (e.g. enzyme assays for genetic metabolic
disorders such as lysosomal storage diseases)
(v) In transition from research into routine practice (e.g.
cytokines)
In principle, evaluation of a new test in a specialist
laboratory is attractive for a number of reasons. As well as
having the necessary infrastructure (in particular, staff
expertise and relatively complex equipment), specialist
laboratories receive specimens from numerous other
centres and consequently can accrue data on test perfor-
mance – both analytical and clinical – relatively rapidly.
Provided appropriate patient information is collected and
collated according to rigorous standards approaching those
of clinical trials, evaluation results obtained in the research
setting can be conﬁrmed in the specialist laboratory,
although this potential could probably be more effectively
exploited than has been the case in the past. Specialist
laboratories are also very well placed to facilitate and
encourage assay standardization, including development of
the reference materials and reference methods that are
essential to establish both what is being measured and what
constitutes an accurate quantitative value [19]. These stan-
dardization activities would provide a sound basis – under-
pinning well-documented quality objectives and helping to
reduce delays such as those encountered previously for PSA
[7] and other analytes – for the transfer of a new test to
multiple platforms prior to implementation in the routine
clinical laboratory.
2.3 Taking a new biomarker into the routine clinical
laboratory
Critical requirements for introducing a new biomarker into
the routine clinical laboratory are perhaps best considered
under three broad headings, i.e. those requirements
reﬂecting broad overall policy (including funding arrange-
ments and the need for user education), those related to
logistical requirements within the laboratory, and those
related to the involvement of diagnostics companies in
making the new biomarker available on an automated
analyzer. For all three, early discussion between relevant
clinical, laboratory and/or diagnostic company staff is highly
desirable. In the past, this has most often relied on personal
or institutional contacts but increasingly more formal
arrangements are being developed. These also provide an
excellent opportunity to encourage early attention to
ensuring quality assurance, development of reference
materials and assay standardization. A prototype example is
the Biomarkers Consortium, a major public–private
biomedical research partnership of 24 companies and 30
non-proﬁt organizations which is managed by the Founda-
tion for National Institutes of Health with the aim of
encouraging the effective identiﬁcation and deployment of
biomarkers (Foundation for the National Institutes of
Health: The Biomarkers Consortium. 2010; http://
www.fnih.org/work/key-initiatives/biomarkers-consortium).
2.3.1 Pre-requisites for success in bringing a new
biomarker into routine practice – a broad
policy perspective
Increasing pressure to demonstrate that healthcare is both
evidence based and cost effective means that, without
convincing evidence that a proposed new test will have a
beneﬁcial effect on patient outcome, a new biomarker is
unlikely to be introduced in any publicly funded healthcare
system [20, 21]. It is essential that evidence supporting
introduction of a new test is clearly presented, comprehen-
sive and independently conﬁrmed in at least two centres.
Such an approach should address the reluctance some
laboratories may have to accept evaluation data from other
sources, a view that can result in repetition of the same
study. This should be unnecessary if the original studies are
well designed, appropriately designed and well documented
although veriﬁcation of performance (which is fundamen-
tally different) [22] is appropriate when introducing a new
test routinely. Formal recommendations from NICE or
NTAC could provide additional assurance of the validity of
evaluation data.
A business case or plan for funding a proposed new test
is essential, and very careful consideration must also be
given to the workload implications of making the test
available and how best to manage demand.
2.3.2 Pre-requisites for success in bringing a new
biomarker into routine practice – regulatory
aspects
A signiﬁcant issue in the development cost of a new
biomarker – and one which also may contribute to delay in
its reaching clinical use – is the need to meet requirements
for regulatory approval in Europe and/or the United States.
These differ, with current European requirements perhaps
tending to focus more on analytical validation and those in
the United States on clinical validity. The European In Vitro
Diagnostic Medical Devices Directive, which in its Appendix
1 deﬁnes minimum requirements that must be met by in
vitro diagnostic devices, is currently being revised and
signiﬁcant tightening of the requirements is anticipated
(http://www.bivda.co.uk). It is neverthless helpful to
consider current requirements which undoubtedly inﬂuence
how rapidly a new test is introduced.
In Europe, the application of a CE mark by the manu-
facturer (or their authorized agent) means that the diag-
nostic meets the requirements of the Directive and is
Proteomics Clin. Appl. 2010, 4, 892–903 897
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This relies on self-certiﬁcation by the manufacturer
supported by relevant technical data. Requirements are
more stringent for some tests (e.g. blood grouping, HIV and
PSA) and a Notiﬁed Body must be involved. More recent test
technologies, developed since the last revision of the
Directive, while within its scope do not ﬁt well within the
current Directive requirements.
In the United States, there are three pathways to test
approval. The simplest pathway is for laboratory-developed (or
home brew) tests, which must meet speciﬁed regulatory
requirements for analytical validation, quality control, external
validation, personnel qualiﬁcations, training and documenta-
tion under the Clinical Laboratory Improvement Amendment
federal regulations. Usually, these tests are not reviewed by
the Food and Drug Administration. The second (510k)
pathway is for clearance of commercially available assays and
involves a comparison and some evidence of clinical
comparability with an existing cleared or approved test. The
third pathway is pre-market approval, which requires a clinical
trial and evidence of adequate clinical performance. This is
required for devices considered to be in high-risk categories
(e.g. tumour markers and HIV tests). There is a high cost for
assuring regulatory compliance in the United States, which is
reﬂected in the different test menus for automated analyzers
marketed in both the United States and the European Union.
There are a considerable number of tests that are not available
in the United States and often a several year lag between
availability of a test in the United States and Europe. The
approach in the United States is perhaps more difﬁcult to
apply rigorously, because measures of clinical sensitivity and
speciﬁcity depend substantially on the population tested and
are not entirely a characteristic of the test. It is often forgotten
that claimed ﬁgures for clinical sensitivity and speciﬁcity
should be qualiﬁed with the statement that these were derived
in a speciﬁc population of well-characterized subjects and may
not apply for patients with different characteristics.
2.3.3 Assessing the impact of a new biomarker on
patient outcome
A new biomarker is only likely to be useful if three
circumstances apply: (i) that the biomarker results are
appropriate precisely for the required application, (ii) that
the marker results separate patients into two or more
populations whose outcomes differ so signiﬁcantly that
clinicians would treat the two groups differently and (iii)
that the divergence of outcomes for patients stratiﬁed for
treatment according to their biomarker results is reliable
[23]. Availability of effective treatment interventions is
usually an essential pre-requisite for improving outcome.
Demonstrating the effect of biomarker measurement on
patient outcome is complex for a number of reasons. As has
recently been elegantly described, clinicians use biomarker
results (e.g. troponin) together with physical observations (e.g.
symptoms of a coronary event) to decide whether to initiate
further intervention (e.g. cardiac catheterization) which may
improve future outcome (e.g. mortality rate) [24]. It is clearly
difﬁcult to differentiate the many contributory variables –
which are likely to be inﬂuenced not only by study design but
also by the patient population studied [25] – and a major
problem in demonstrating effect is the remoteness of outcome
from the test result [24]. In this context, multivariate analysis is
essential. By taking into account the contributions of other
biomarkers or clinical factors, multivariate analysis allows an
assessment of the extra predictive effect of adding a novel
marker to the current clinical and biochemical diagnostic tools
used in a particular disease or pre-disease state. It is instructive
to discover that, despite many articles describing the diagnostic
performance of serum Heart-type Fatty Acid Binding Protein
since its proposal as a marker of Acute Coronary Syndrome
(ACS) in 1988, multivariate analysis in patients suspected of
ACS has been published only as recently as 2010 [26].
Intelligently designed randomized controlled trials, which
adhere to the recommendations of the CONSORT statement
[24, 27] and the REMARK guidelines [25] are likely to become
more widely used in the early assessment of new biomarkers.
Modeling studies may cost-effectively complement such trials
as they permit simulation of the effect of testing in much larger
populations than can be achieved in clinical trials. Appropriate
information both about the diagnostic accuracy of the test and
about the effect of consequent treatment decisions in a well-
deﬁned patient group is essential for modeling studies. Such
studies can be particularly helpful in deﬁning required para-
meters of analytical performance by assessment of the effect of
bias and imprecision, as has been demonstrated for measure-
ment of PSA in a screening context [28] and for use of glucose
meters in patients on intensive insulin treatment [29].
Modeling studies can readily provide valuable insight
into analytical criteria that must be met, inform develop-
ment of appropriate protocols and predict the downstream
consequences of testing. However, they are less likely to be
able to provide information about clinical outcomes
including morbidity, mortality, length of stay in hospital or
readmission rates, all of which are best assessed through
carefully designed audit studies.
Proposed introduction of a new biomarker will in some
cases be supported by guideline recommendations, but in
practice this is more likely to be the case when the
biomarker is already reasonably well established.
2.3.4 Development of a business case for funding a
new biomarker
The cost of biomarker analysis is generally much less than
that associated with therapeutic interventions or other
diagnostic procedures such as magnetic resonance imaging
and is likely to represent only a fraction of the cost of a
patient episode. Cost studies have therefore often not been
considered when the biomarker is one small cog in an
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viewpoint, ensuring that an appropriate reimbursement
mechanism is in place is essential before introducing a new
biomarker. This minimizes the risk of the laboratory ulti-
mately carrying the costs for unfunded tests upon which
clinicians have come to rely, as has occasionally happened in
the past. How the business case is prepared will depend on
local, regional and/or national funding arrangements and
should include consideration of how introduction of the new
test would lead to cost savings elsewhere in the health
system (e.g. as reﬂected in fewer admissions to hospital,
decreased requirement for more expensive radiological
studies, more efﬁcacious prescribing of medication). One of
the best examples is in breast cancer, where relatively
inexpensive measurement of HER2 status ensures that the
costly companion drug Herceptin
s is only prescribed to
those patients likely to beneﬁt. The annual cost for a UK
patient on Herceptin
s has been estimated by BIVDA to be
£20000 per year, whereas the cost for the screening test to
identify HER2 positive patients is about £225 and the initial
screen using immunochemistry is much less than this
(http://www.bivda.co.uk).
If business cases for new tests were developed regionally or
nationally under the auspices of NTAC, the Department of
Health, or another funding body (after careful consideration
of relevant evidence including the predicted impact of the new
test on the patient pathway), and reviewed centrally, this could
be more efﬁcient than current practice, as well as encouraging
more uniform introduction of the test.
2.3.5 Managing demand for a newly introduced test
Although 70–80% of all healthcare decisions affecting diag-
nosis or treatment involve a pathology investigation [30], it is
also the case that over-requesting of many biochemistry tests is
widespread, with estimates varying from 25–40% to up to 98%
in one study (http://www.dh.gov.uk/en/Publicationsand-
statistics/Publications/PublicationsPolicyAndGuidance/DH_
091985). It has recently been suggested that eliminating
inappropriate testing could save the NHS up to £1 billion per
annum in test costs alone [8]. Although major efforts are now
being made to address this retrospectively for established
tests [8], introducing a new biomarker – whether to replace a
previous test (e.g. troponin replaced lactate dehydrogenase
isoenzyme and also to some extent creatine kinase-MB
isoenzyme measurements), or to introduce a new parameter
(e.g. brain natriuretic peptide) – provides a unique opportu-
nity to implement appropriate requesting patterns from the
beginning. This was achieved with some success when
troponin testing was introduced, when many hospitals
limited the test to carefully deﬁned patient groups and often
required consultant approval for requests. Other approaches
have also been described [8], and such activity, which is
integral to service development and improvement, should be
given high priority when introducing a new biomarker. An
effective means of educating users about requesting, prefer-
ably electronically at the time the request is made, is almost
certainly the most vital component for success. It is of course
also essential to ensure that all tests that the new biomarker
should replace are fully withdrawn. Some approaches that
may encourage adoption of new practice (e.g. not ordering
radiological scans when replaced by a new biomarker) have
been previously described [31].
2.4 Pre-requisites for success in bringing a new
biomarker into routine practice – a broad
logistical perspective
In order to consider the pre-analytical and analytical
requirements for efﬁciently introducing a new biomarker
into the routine high-throughput laboratory, it is essential to
have an appreciation of how such laboratories operate.
Table 3 summarizes some relevant ﬁgures for a typical UK
teaching hospital which is one of three adult hospitals
serving a population of approximately 1 million people. The
ﬁgures show the typically high throughput of a modern
clinical biochemistry laboratory, where any requirement for
special handling outwith the established workﬂow is likely
to be problematic.
2.4.1 Pre-analytical considerations in the routine
laboratory
Numerous different types of specimen – primarily blood
and urine but also cerebrospinal or pancreatic ﬂuids, semen,
microbiological swabs and others – arrive at the laboratory
reception desk, where are they sorted according to the test
requirements for processing and storage. Specimens are
usually bar coded during the booking-in process, at which
time patient details and the tests required are entered into
the laboratory computer. Increasingly, many of these
processes are at least partially automated. Although speci-
mens from within the hospital may be delivered by porters
or through pneumatic tube systems from ward or clinic to
the laboratory, those from other hospitals or general practice
arrive by van and hence the delay from time of sampling to
processing may exceed 16h.
Table 3. Workload ﬁgures for a typical UK acute teaching hos-
pital clinical biochemistry laboratory
Statistic Number
Population served 750000
Number of beds 800
Number of samples/year 750000
a)
Number of samples/day 2200
Number of samples/hour at peak time (between 2 and
6 pm on weekdays)
500
a) Representing 5.0 million tests requested in total.
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measurable in blood, serum or urine, should be reasonably
robust and should not require special handling or storage in
transit to the laboratory. The likelihood of having to reject
specimens as unsuitable tends to be higher if there are
special requirements, e.g. having to separate and freeze
plasma specimens for adrenocorticotropic hormone within
15min of collection.
As discussed previously, it is very helpful if there are no
speciﬁc timing requirements or a need for multiple samples
on different days. Even for well-established tests such as
testosterone in males or progesterone in females, failure of
requestors to ensure that specimens are timed appropriately
(i.e. between 8 and 11 am or 7 days prior to the next expected
menstrual cycle respectively) means that results obtained
are often meaningless and a signiﬁcant number of tests
have to be repeated, at additional cost as well as incon-
venience to the patient. Early awareness of potential effects
on results for a new biomarker of relevant medications,
illness or intervention (e.g. respectively, oral contraceptive
medication on luteinizing hormone, non-thyroidal illness
on thyroid hormones or prostatic biopsy on PSA) is also
highly desirable although inevitably some caveats are only
likely to be identiﬁed with increasing use of the test.
Indiscriminate test requesting without ﬁrst considering
carefully whether the result is likely to be helpful or relevant
is always undesirable. Clear and speciﬁc information about
the clinical circumstances in which a new biomarker is to be
used should therefore be widely and proactively dissemi-
nated – in advance of the test being made available as well as
during and after its introduction. Early inclusion of details
of a new test in existing information resources such as Lab
Tests On Line (http://www.labtestsonline.org.uk/) and the
National Library of Medicine Catalogue (http://nlmc.
x-labsystems.co.uk/) is highly desirable.
Unexpected over-requesting will of course affect cost
analyses undertaken prior to introduction of the test, a
problem that can also occur when a test previously offered
only by specialist referral laboratories is made available in a
routine laboratory. Figure 1 shows what happened in one
hospital when measurement of C-reactive protein (CRP), an
acute phase reactant, was transferred from a unit in which
the turn-around time (sample receipt to result issue) was
2wk to a clinical biochemistry department which provided a
turn-around time of 20min. Although the move had been
predicted to be cost neutral, as a consequence of the much
improved service provided (including availability of the test
on the clinical biochemistry request form), the workload
increased nearly sevenfold over as many years and the cost
of providing CRP measurements is now the highest of any
single test in the laboratory. Since it is unlikely that the
clinical need for CRP measurement has increased to this
extent in a laboratory where use of ultrasensitive CRP is not
being promoted, the main cause is almost certainly inap-
propriate requesting, a problem that has been encountered
elsewhere for CRP, although somewhat less dramatically
[32]. In the latter study, strategies to control demand were
introduced and successfully reduced the number of requests
from acute admission units.
2.4.2 Analytical considerations in the routine
laboratory
As a consequence of the high workload and perceived need
for rapid turn-around time in routine clinical biochemistry
laboratories, assay automation is essential for almost every
test. There is little staff time for manual assays or complex
trouble-shooting and – as during the pre-analytical phase –
any complicated processes are likely to be difﬁcult to
incorporate. This may be exacerbated in the future by
proposed workforce changes in the United Kingdom which
may lead to operation of automated analyzers by less highly
trained staff.
As summarized in Table 2, a new biomarker must, of
course, fulﬁll standard quality requirements for good
performance, including those of relevant regulatory autho-
rities. Prior to providing results for clinical specimens,
veriﬁcation studies to conﬁrm that the method is perform-
ing as expected should be undertaken following a deﬁned
protocol such as that developed by the UK Association for
Clinical Biochemistry [22].
Robust internal quality control procedures must also be
in place. EQA is not likely to be available until a reasonable
number of laboratories (often a minimum of ten) offer the
test. In the absence of an EQA or proﬁciency testing
scheme, informal exchange of samples among laboratories
offering the test can provide some assurance that results are
similar and may highlight potential difﬁculties at an early
stage, when it is relatively easy to address them. Exchanging
information about possible clinically relevant interferences
and other aspects of best practice – including appropriate
reference intervals, decision limits and interpretation – is
also very helpful.


























Figure 1. Effect on workload of transferring measurement of CRP
from a specialist to a routine laboratory.
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laboratory
Appropriate reference interval data should be readily avail-
able from the laboratory together with clear guidance about
clinical interpretation of results in relevant patient groups.
This is particularly important for a newly introduced
biomarker since clinical staff will not be familiar with the
new test and its limitations. Laboratory staff can play a
major role in collecting audit data required to assess test
performance in routine clinical practice. Recording any
unexpected or atypical results and discussing these at an
early stage with clinical colleagues is also highly desirable.
Effective clinical audit studies should also be conducted to
evaluate whether introduction of the new test has met
expectations and to identify any problems at an early stage.
2.5 Pre-requisites for success in bringing a new
biomarker into routine practice – automation
and the diagnostics industry
As indicated above, automation is essential in modern high-
throughput laboratories. Operational procedures are relatively
straightforward and involve maintaining the analyzer and
checking internal quality control specimens several times
daily, according to the manufacturers’ instructions and strictly
deﬁned protocols. Reagents are kept on board the machine
and specimens are loaded as they arrive. The analyzer reads
the bar code on each specimen and determines which tests are
to be done. Once results have been technically validated by the
operator, they are automatically downloaded to the laboratory
computer for clinical authorization and before being uploaded
to the hospital information system.
Major analytical advantages of automated analyzers as
compared with manual assays include the convenience and
speed of analysis (e.g. test results can be available at any time of
day or night, often within 20min), the possibility of assaying
samples as they arrive (i.e. ‘‘random access’’) rather than in
batches, and the excellent precision achievable (i.e. superior to
that achievable with manual pipetting). Logistically, their
relative simplicity means that all staff can readily be trained to
use the analyzer, bar-coded primary tubes can be used to
minimize the risk of error, and capacity is not an issue.
When considering introducing a new biomarker to the
routine laboratory, there are additional issues associated
with assays that rely on other technologies such as mass
spectrometry as well as with immunoassay methods which
require transfer to an automated platform.
2.5.1 Mass spectrometry in the routine clinical
biochemistry laboratory
There is ever-increasing interest in clinical biochemistry
laboratories in introducing mass spectrometric procedures
for established analytes including steroids, vitamin D and
therapeutic drugs such as cyclosporine and tacrolimus.
These analytes are difﬁcult to measure reliably by immu-
noassay methods, which tend to be less speciﬁc and more
prone to interference than mass spectrometric techniques.
The major drivers for replacing immunoassay with the latter
are increased analytical quality and decreased cost, as the
savings on immunoassay reagents can rapidly recoup the
initial purchase price of a mass spectrometer.
Although availability of mass spectrometry in routine
laboratories is attractive when considering introducing a new
biomarker developed on such a system, it is important to be
aware of some caveats. It is unlikely to be feasible to train all
staff in this specialized technique. In one clinical laboratory
offering a tacrolimus service by mass spectrometry, only 30%
of staff are trained to run the instrument as compared with all
staff for the automated immunoassay analyzer previously
used for tacrolimus. In the same laboratory, capacity is an
issue and the instrument requires a dedicated member of
staff for the whole day to complete the workload, i.e. much
more hands-on time than required for the immunoassay
analyzer, which is essential a ‘‘walk-away’’ instrument. These
issues make staff deployment more complicated. In addition,
relatively complex sample manipulation is required, some of
which is not in bar-coded tubes, making sample handling
errors more likely. Accurate pipetting, a skill which unfor-
tunately can no longer be assumed in some highly automated
laboratories, is also essential. Until mass spectrometric
procedures can be simpliﬁed considerably and ideally auto-
mated, immunoassay is likely to continue to have a major
role in routine laboratories.
2.5.2 Transfer of new biomarkers onto automated
analyzers
From a commercial perspective, transfer of a new biomarker
onto an existing analytical platform requires signiﬁcant
ﬁnancial commitment and is wholly dependent on the
conviction of at least one diagnostics company that the test
will become widely used. This requires not only that all the
test characteristics previously described are satisfactorily
met but also that the development costs of automation will
ultimately be recouped and provision of the test will be
ﬁnancially proﬁtable. Some reworking of the test may be
required to ensure that it runs optimally on the platform [33]
and provides results identical to those obtained with earlier
manual assays. As discussed above, regulatory aspects are
critical and a clinical trial using the assay in its ﬁnal form is
usually necessary [33].
3 Future prospects
New biomarkers can be taken from research into routine
practice provided there is sound evidence of clinical utility,
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that the test is done only for those likely to beneﬁt, analytical
procedures are simple and robust, and quality is veriﬁed
through internal quality control and EQA/proﬁciency test-
ing procedures. For these requirements to be met in a
timely manner for a speciﬁc biomarker, it is necessary to
learn from past mistakes and perhaps to think differently in
the future.
Exemplifying the need to learn from past mistakes, an
early audit following introduction of troponin testing in a
UK hospital, for example, demonstrated no advantage to
patients or the NHS of the test in selecting patients for
further cardiac investigation and/or reducing length of stay
[34]. Reasons identiﬁed for this most unexpected conclusion
were simple. As reagents were not stable enough to allow
continuous access of samples, they were run in batches and
the intended turn-around time was not met in 29% of cases.
In addition, 80 of 109 requests had no information regard-
ing timing of the blood sample in relation to the clinical
indication and no indication was even given for 39% of
requests. As described above, this illustrates how consider-
able care and attention to detail is required at every stage of
evaluation, development and ultimately routine measure-
ment of a new biomarker.
For the future, much improved involvement and colla-
boration of all interested parties – including experts in
discovery and assay development, in health policy, in clinical
trial units, in the diagnostics industry and in laboratories
responsible for providing clinical testing – will almost
certainly lead to earlier identiﬁcation and implementation of
promising new biomarkers.
In a unique prototype project funded by the UK NHS
National Institute of Health Research, the possibilities
of such collaboration are currently being explored with the
aim of developing a rigorous evidence-based approach to
protein biomarker evaluation (Biomarker evaluation and
translation. An NHS National Institute of Health Research
programme in renal and liver diseases. 2010; http://
www.biomarkerpipeline.org/nihr/programme.html). The
programme is made up of three closely related and inter-
dependent strands. In the ﬁrst strand, a multi-disciplinary
team of health methodologists and statisticians are under-
taking modelling studies to deﬁne aspects of best practice in
evaluation new tests. In the second analytical strand, clinical
scientists are reviewing and identifying potential biomar-
kers, developing ELISAs for rapid preliminary evaluation
of their clinical potential, and then undertaking more
rigorous assessment of the most promising markers
using well-characterized banked specimens. In the third
strand, a randomized controlled trial is being conducted
to assess the clinical value to the NHS of a panel of
biomarkers that will be available on a commercial platform.
Although there are inevitably some challenging issues, this
approach may provide a helpful prototype for more rapid
introduction of useful new tests into the routine clinical
laboratory.
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